BCLI - התחייבויות לטווח ארוך להון brainstorm-cell.com

The daily price chart for Brainstorm Cell (BCLI), which currently stands at 0.00, is based on the neuron regeneration potential of the NurOwn platform. Drug approval will grant the company full pricing power due to the critical nature of the therapy. Business efficiency relies on the flawless transportation of biomaterials in liquid nitrogen. Stable development is guaranteed by a highly qualified staff of scientists retained through a stock option system.

The metric is calculated as the ratio of liabilities with a maturity exceeding one year to the market value of equity. It determines the business's degree of dependence on external financing and its financial stability. For Brainstorm Cell (BCLI), such a debt structure supports diversified research and development in the field of neurodegenerative diseases. This mitigates regulatory risks by allocating resources across various programs. The trend in the long-term debt-to-equity ratio reflects the company's current level of financial leverage.